Frontiers | Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges | Oncology
The CLL14 trial: longer progression-free survival for CLL patients with coexisting conditions treated with venetoclax | 2 Minute Medicine
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions | NEJM
Practical Guidelines on Optimizing CLL Care in the Era of Molecular Therapies - Optimizing CLL Care - Module - Optimizing CLL Care - Oncology - Clinical Care Options
Design of the CLL14 study. CLL = chronic lymphocytic leukemia; CIRS =... | Download Scientific Diagram
Lymphoma Hub Twitterissä: "CONGRESS | #EHA24 | C Schneider presents the CLL14 trial results of patients with comorbidities receiving front-line obinutuzumab + chlorambucil or venetoclax #lymsm https://t.co/wvnfF8EAf9" / Twitter
Updates from the American Society of Hematology 2019 annual meeting: practice-changing studies in treatment-naïve chronic lymphocytic leukemia. - Abstract - Europe PMC
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions | NEJM
VENCLEXTA® (venetoclax tablets) | CLL14 & MURANO Clinical Trial Study Designs
Fixed Duration Venetoclax + Obinutuzumab - CLL14 Trial Update - CLL Pharmacist
Practical Guidelines on Optimizing CLL Care in the Era of Molecular Therapies - Optimizing CLL Care - Module - Optimizing CLL Care - Oncology - Clinical Care Options
PDF) Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial
GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG.... EHA Library. Stilgenbauer S. Jun 14 2019; 267306
Life | Free Full-Text | Druggable Molecular Pathways in Chronic Lymphocytic Leukemia | HTML
Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia - ScienceDirect
FIXED-DURATION VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED.... EHA Library. Al-Sawaf O. Jun 12 2020; 294975
Health‐related quality of life with fixed‐duration venetoclax‐obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial - Al‐Sawaf - 2021 - American Journal of Hematology - Wiley
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study | Journal of Clinical Oncology
VENCLEXTA® (venetoclax tablets) | CLL14 & MURANO Clinical Trial Study Designs
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
Fixed Duration Venetoclax + Obinutuzumab - CLL14 Trial Update - CLL Pharmacist
